Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > News Release Out

<< Previous

Bullboard Posts

Next >>

Comment by woundedkneeon Aug 06, 2020 8:24am

256 Views

Post# 31371366

RE:News Release Out

What a huge waste of money. It is not my opinion.. it is a fact! I have never seen any IR firm being referenced by any company, giving them (the IR firm) credit for an increase in exposure and/or most importantly an increase in the stock price. Surely Antibe"s management must to be able to get the word out much cheaper. How about on Twitter, Facebook,etc. Or just plain old word of mouth. EG. pssst.. hey buddy, wanna hot tip in the market? What about the analysts who are now covering the stock?

<< Previous

Bullboard Posts

Next >>

Three mispriced stocks exposed to major market tailwinds